Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2019

View Archived Issues

Glial alpha-synuclein causes neuronal toxicity

Decoy platelets for thrombosis, metastasis

How microbiome cell toxin damages host cell DNA

MAPK4 blockade inhibits AKT/mTOR pathway and shows promise for cancer therapy

Fatty acid transporter CD36 inhibition could be beneficial in prostate cancer

Allakos presents results from phase I study of AK-002 in indolent systemic mastocytosis

First patient dosed in phase II study of NYX-783

Gamida Cell and Editas Medicine to study CRISPR editing of NAM-NK cells

Funding continues for Aravive's anti-GAS6 fusion protein development

Discovery and characterization of novel PROTAC AR degrader, ARD-69

First-in-human results presented for SynGEM vaccine

GlaxoSmithKline Intellectual Property divulges PI3K inhibitors

Merck & Co. describes new IDO1 inhibitors

Inosine supplementation and modulation of adenosine deaminase as a potential therapy against ALS

Jazz Pharmaceuticals identifies compounds for sleep disorders

Vical discontinues phase II trial of VL-2397 as it pursues strategic alternative review process

Search for alternative Notch 1 pathway modulators leads Novartis to NVS-ZP7-4

Semma Therapeutics divulges new compositions for diabetes

GlaxoSmithKline Biologicals patents adenoviral vectors for CHIKV infections

AlzProtect completes phase I food effect study with AZP-2006

FDA approves Esperoct for hemophilia A

EZH2 inhibitors may be a means of treating scleroderma

Catabasis reports growth data from phase II trial of edasalonexent for Duchenne muscular dystrophy

ReNeuron reports vision improvement in first phase II cohort with hRPC cell therapy for RP

FDA places partial clinical hold on phase I study of XmAb-14045

Phase II trial of VAL-083 in newly diagnosed GBM achieves halfway enrollment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...